Literature DB >> 19437531

Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats.

Pawel Wiczling1, Sihem Ait-Oudhia, Wojciech Krzyzanski.   

Abstract

We have proposed a technique for transforming reticulocyte (RET) flow cytometry count into the age distribution allowing for a quantitative characterization of RETs dynamics. This technique was evaluated in homeostatic and erythropoietically stimulated rats. We administered a single intravenous dose (4,050 IU/kg) of recombinant human erythropoietin to Wistar rats, then stained their RETs with thiazole orange, and measured the distribution of the fluorescent signal using flow cytometry. The RET age distribution was determined assuming an exponential decline of RET RNA. The RET distribution over time was characterized by median age, production rate of mature red blood cell in the blood, bone marrow and blood maturation times, and RET loss from the blood. Erythropoietin was found to cause complex changes not only in RET count but also in age distribution. Generally, an increase in RET count was accompanied by the presence of young RETs and a decrease with the presence of old RETs. The rate at which RETs were removed from the blood was affected considerably by erythropoietin administration, and their death was attributed to it. Flow cytometric analysis of RET age distribution expands our understanding of erythropoiesis and augments the information we can obtain from RET measurements. 2009 International Society for Advancement of Cytometry.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19437531     DOI: 10.1002/cyto.a.20736

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  9 in total

Review 1.  Pharmacodynamic models of age-structured cell populations.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-16       Impact factor: 2.745

2.  Application of Reticulocyte-Based Estimation of Red Blood Cell Lifespan in Anemia Management of End-Stage Renal Disease Patients.

Authors:  Ly Minh Nguyen; Calvin J Meaney; Gauri G Rao; Mandip Panesar; Wojciech Krzyzanski
Journal:  AAPS J       Date:  2020-02-03       Impact factor: 4.009

3.  Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-24       Impact factor: 2.745

4.  Reticulocyte-based estimation of red blood cell lifespan.

Authors:  Wojciech Krzyzanski; Michael E Brier; Timothy M Creed; Adam E Gaweda
Journal:  Exp Hematol       Date:  2013-05-24       Impact factor: 3.084

5.  Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.

Authors:  Xiaoyu Yan; Sihem Ait-Oudhia; Wojciech Krzyzanski
Journal:  Pharm Res       Date:  2012-11-28       Impact factor: 4.200

6.  Development of an erythropoietin prescription simulator to improve abilities for the prescription of erythropoietin stimulating agents: is it feasible?

Authors:  Luca Gabutti; Filippo Nobile; Valentina Forni; Fabio Rigamonti; Nadir Weibel; Michel Burnier
Journal:  BMC Nephrol       Date:  2011-02-18       Impact factor: 2.388

7.  A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats.

Authors:  Ly Minh Nguyen; Zhichuan Li; Xiaoyu Yan; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-06-07       Impact factor: 2.745

8.  A Systems Pharmacology Model of Erythropoiesis in Mice Induced by Small Molecule Inhibitor of Prolyl Hydroxylase Enzymes.

Authors:  I Singh; E E Nagiec; J M Thompson; W Krzyzanski; P Singh
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-02-11

9.  Flow Cytometry as a Tool for Quality Control of Fluorescent Conjugates Used in Immunoassays.

Authors:  Marta de Almeida Santiago; Bruna de Paula Fonseca E Fonseca; Christiane de Fátima da Silva Marques; Edimilson Domingos da Silva; Alvaro Luiz Bertho; Ana Cristina Martins de Almeida Nogueira
Journal:  PLoS One       Date:  2016-12-09       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.